Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

10 сентября 2019 г. обновлено: Eli Lilly and Company

A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy

The purpose of this study is to gather information about the use of an investigational drug called Ramucirumab in adenocarcinomas of the stomach or gastroesophageal junction.

Обзор исследования

Статус

Завершенный

Условия

Вмешательство/лечение

Подробное описание

Placebo-controlled, multicenter Phase 3 study of participants with metastatic gastric cancer [including adenocarcinomas of the gastroesophageal junction (GEJ)] and disease progression on standard first-line chemotherapeutic regimens. Participants will be randomized on a 2:1 basis to receive best supportive care plus ramucirumab administered every 2 weeks or best supportive care plus placebo administered every 2 weeks, respectively. Participants will undergo radiographic assessment of disease status every 6 weeks. Participant will be treated until there is evidence of progressive disease, toxicity requiring cessation, withdrawal of consent, or until other withdrawal criteria are met.

Approximately 348 participants, with histologically- or cytologically-confirmed, metastatic gastric or GEJ adenocarcinoma, and radiographically measurable disease as defined by the Response Evaluation Criteria in Solid Tumors or evaluable, nonmeasurable disease, will be randomized. Participants will be enrolled from approximately 250 study centers in North America, South America, Central America, Asia, Australia, New Zealand, and Europe.

Тип исследования

Интервенционный

Регистрация (Действительный)

355

Фаза

  • Фаза 3

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Места учебы

  • Австралия
      • Bedford Park, Австралия, 5042
        • ImClone Investigational Site
      • St. Leonards, Австралия, NSW 2065
        • ImClone Investigational Site
      • Woodville, Австралия, 5011
        • ImClone Investigational Site
    • New South Wales
      • Wodonga, New South Wales, Австралия, 3690
        • ImClone Investigational Site
    • Tasmania
      • Hobart, Tasmania, Австралия, 7000
        • ImClone Investigational Site
    • Victoria
      • East Melbourne, Victoria, Австралия, 3002
        • ImClone Investigational Site
    • Western Australia
      • Perth, Western Australia, Австралия, 6000
        • ImClone Investigational Site
  • Аргентина
      • Buenos Aires, Аргентина, 1425
        • ImClone Investigational Site
      • Capital Federal, Аргентина, 1264
        • ImClone Investigational Site
      • Ciudad Autonoma de Buenos Aires, Аргентина, C1437JCP
        • ImClone Investigational Site
      • Ciudada Autonoma, Аргентина, C1199ABD
        • ImClone Investigational Site
      • Cordoba, Аргентина, 5000
        • ImClone Investigational Site
      • Rosario, Аргентина, S2002KDS
        • ImClone Investigational Site
  • Босния и Герцеговина
      • Sarajevo, Босния и Герцеговина, 71000
        • ImClone Investigational Site
  • Бразилия
      • Barretos, Бразилия, 14784-400
        • ImClone Investigational Site
      • Belo Horizonte, Бразилия, 30150-281
        • ImClone Investigational Site
      • Belo Horizonte, Бразилия, 30110-090
        • ImClone Investigational Site
      • Brasilia, Бразилия, 70390-150
        • ImClone Investigational Site
      • Curitiba, Бразилия, 80730-130
        • ImClone Investigational Site
      • Curitiba, Бразилия, 81520-060
        • ImClone Investigational Site
      • Florianopolis, Бразилия, 88034-000
        • ImClone Investigational Site
      • Ijui, Бразилия, 98700-000
        • ImClone Investigational Site
      • Lajeados, Бразилия, 95900-000
        • ImClone Investigational Site
      • Londrina, Бразилия, 86050-190
        • ImClone Investigational Site
      • Passo Fundo, Бразилия, 99010-260
        • ImClone Investigational Site
      • Porto Alegre, Бразилия, 90035-903
        • ImClone Investigational Site
      • Porto Alegre, Бразилия, 90610-970
        • ImClone Investigational Site
      • Porto Alegre, Бразилия, 90840-440
        • ImClone Investigational Site
      • Sao Paulo, Бразилия, 01406-100
        • ImClone Investigational Site
  • Гватемала
      • Guatemala, Гватемала, 01010
        • ImClone Investigational Site
      • Guatemala, Гватемала
        • ImClone Investigational Site
  • Египет
      • Alexandria, Египет, 21131
        • ImClone Investigational Site
      • Cairo, Египет, 11796
        • ImClone Investigational Site
  • Индия
      • Bangalore, Индия, 560 029
        • ImClone Investigational Site
      • Chennai, Индия, 600010
        • ImClone Investigational Site
      • Hyderabad, Индия, 500 033
        • ImClone Investigational Site
      • Hyderabad, Индия, 500004
        • ImClone Investigational Site
      • Kolkata, Индия, 700053
        • ImClone Investigational Site
      • Mumbai, Индия, 400 012
        • ImClone Investigational Site
      • Mumbai, Индия, 400016
        • ImClone Investigational Site
      • Pune, Индия, 411001
        • ImClone Investigational Site
      • West Bengal, Индия, 700054
        • ImClone Investigational Site
    • Andh Prad
      • Hyderabad, Andh Prad, Индия, 500004
        • ImClone Investigational Site
      • Hyderabad, Andh Prad, Индия, 500033
        • ImClone Investigational Site
    • Delhi
      • New Delhi, Delhi, Индия, 110085
        • ImClone Investigational Site
    • Karna
      • Bangalore, Karna, Индия, 560 025
        • ImClone Investigational Site
      • Bangalore, Karna, Индия, 560054
        • ImClone Investigational Site
    • Kerala
      • Cochin, Kerala, Индия, 682304
        • ImClone Investigational Site
      • Thiruvananthapuram, Kerala, Индия, 695011
        • ImClone Investigational Site
      • Trivandrum, Kerala, Индия, 695011
        • ImClone Investigational Site
    • Kilpauk
      • Chennai, Kilpauk, Индия, 600 010
        • ImClone Investigational Site
    • Madh Prad
      • Bhopal, Madh Prad, Индия, 462001
        • ImClone Investigational Site
      • Indore, Madh Prad, Индия, 452008
        • ImClone Investigational Site
    • Mahara
      • Mumbai, Mahara, Индия, 400016
        • ImClone Investigational Site
      • Nashik, Mahara, Индия, 422 004
        • ImClone Investigational Site
      • Pune, Mahara, Индия, 411001
        • ImClone Investigational Site
    • Tamilnadu
      • Chennai, Tamilnadu, Индия, 600010
        • ImClone Investigational Site
      • Chennai, Tamilnadu, Индия, 600035
        • ImClone Investigational Site
    • W Bengal
      • Kolkata, W Bengal, Индия, 700053
        • ImClone Investigational Site
      • Kolkata, W Bengal, Индия, 700054
        • ImClone Investigational Site
  • Индонезия
      • Jakarta, Индонезия, 10440
        • ImClone Investigational Site
      • Jakarta, Индонезия, 11420
        • ImClone Investigational Site
      • Jakarta, Индонезия, 14450
        • ImClone Investigational Site
      • Sumatera Utara, Индонезия, 20136
        • ImClone Investigational Site
      • West Java, Индонезия, 40161
        • ImClone Investigational Site
  • Испания
      • Alcorcon, Испания, 28922
        • ImClone Investigational Site
      • Barcelona, Испания, 08036
        • ImClone Investigational Site
      • Barcelona, Испания, 08035
        • ImClone Investigational Site
      • Elche, Испания, 03203
        • ImClone Investigational Site
      • Madrid, Испания, 28034
        • ImClone Investigational Site
      • Santander, Испания, 39008
        • ImClone Investigational Site
      • Sevilla, Испания, 41021
        • ImClone Investigational Site
  • Италия
      • Aviano, Италия, 33081
        • ImClone Investigational Site
      • Bologna, Италия, 40138
        • ImClone Investigational Site
      • Brescia, Италия, 25123
        • ImClone Investigational Site
      • Cremona, Италия, 26100
        • ImClone Investigational Site
      • Lido di Camaiore, Италия, 55043
        • ImClone Investigational Site
      • Lucca, Италия, 55043
        • ImClone Investigational Site
      • Meldola, Италия, 47014
        • ImClone Investigational Site
      • Mirano, Италия, 30035
        • ImClone Investigational Site
      • Noale, Италия, 30033
        • ImClone Investigational Site
      • Potenza, Италия, 85100
        • ImClone Investigational Site
      • Rimini, Италия, 47900
        • ImClone Investigational Site
      • Udine, Италия, 33100
        • ImClone Investigational Site
  • Канада
    • Alberta
      • Edmonton, Alberta, Канада, T6G 1Z2
        • ImClone Investigational Site
    • Quebec
      • Montreal, Quebec, Канада, H2L 4M1
        • ImClone Investigational Site
      • Sherbrooke, Quebec, Канада, J1G 2E8
        • ImClone Investigational Site
  • Колумбия
      • Monteria, Колумбия
        • ImClone Investigational Site
  • Корея, Республика
      • Seoul, Корея, Республика, 120-752
        • ImClone Investigational Site
      • Seoul, Корея, Республика, 135-720
        • ImClone Investigational Site
      • Seoul, Корея, Республика, 136-705
        • ImClone Investigational Site
      • Seoul, Корея, Республика, 137-701
        • ImClone Investigational Site
  • Ливан
      • Beirut, Ливан
        • ImClone Investigational Site
  • Мальта
      • Floriana, Мальта, 1941
        • ImClone Investigational Site
      • Floriana, Мальта, FRN 1941
        • ImClone Investigational Site
  • Мексика
      • Aguascelientes, Мексика, 20217
        • ImClone Investigational Site
  • Новая Зеландия
      • Christchurch, Новая Зеландия, 8011
        • ImClone Investigational Site
  • Польша
      • Gdansk, Польша, 80-219
        • ImClone Investigational Site
      • Krakow, Польша, 31-108
        • ImClone Investigational Site
      • Olsztyn, Польша, 10-513
        • ImClone Investigational Site
  • Российская Федерация
      • Chelyabinsk, Российская Федерация, 454087
        • ImClone Investigational Site
      • Kursk, Российская Федерация, 305035
        • ImClone Investigational Site
      • Moscow, Российская Федерация, 115478
        • ImClone Investigational Site
      • Moscow, Российская Федерация, 125367
        • ImClone Investigational Site
      • Pyatigorsk, Российская Федерация, 357524
        • ImClone Investigational Site
      • St. Petersburg, Российская Федерация, 197022
        • ImClone Investigational Site
      • St. Petersburg, Российская Федерация, 197758
        • ImClone Investigational Site
      • St. Petersburg, Российская Федерация, 195067
        • ImClone Investigational Site
  • Румыния
      • Baia Mare, Румыния, 430031
        • ImClone Investigational Site
      • Cluj Napoca, Румыния, 400015
        • ImClone Investigational Site
      • Cluj Napoca, Румыния, 400058
        • ImClone Investigational Site
      • Suceava, Румыния, 720237
        • ImClone Investigational Site
  • Соединенное Королевство
      • London, Соединенное Королевство, SE1 7EH
        • ImClone Investigational Site
      • Sutton, Соединенное Королевство, SM2 5PT
        • ImClone Investigational Site
      • Wolverhampton, Соединенное Королевство, WV10 0QP
        • ImClone Investigational Site
    • Wirral
      • Bebington, Wirral, Соединенное Королевство, L83 4JY
        • ImClone Investigational Site
  • Соединенные Штаты
    • California
      • Bakersfield, California, Соединенные Штаты, 93309
        • ImClone Investigational Site
      • La Jolla, California, Соединенные Штаты, 92093
        • ImClone Investigational Site
      • Redlands, California, Соединенные Штаты, 92374
        • ImClone Investigational Site
    • Illinois
      • Chicago, Illinois, Соединенные Штаты, 60612
        • ImClone Investigational Site
    • Louisiana
      • New Orleans, Louisiana, Соединенные Штаты, 70112
        • ImClone Investigational Site
    • Massachusetts
      • Boston, Massachusetts, Соединенные Штаты, 02115
        • ImClone Investigational Site
    • Nebraska
      • Omaha, Nebraska, Соединенные Штаты, 68114
        • ImClone Investigational Site
    • New York
      • New York, New York, Соединенные Штаты, 10003
        • ImClone Investigational Site
    • Pennsylvania
      • West Reading, Pennsylvania, Соединенные Штаты, 19611
        • ImClone Investigational Site
    • Rhode Island
      • Providence, Rhode Island, Соединенные Штаты, 02903
        • ImClone Investigational Site
    • South Carolina
      • Charleston, South Carolina, Соединенные Штаты, 29425
        • ImClone Investigational Site
    • Tennessee
      • Knoxville, Tennessee, Соединенные Штаты, 37920
        • ImClone Investigational Site
      • Memphis, Tennessee, Соединенные Штаты, 38119
        • ImClone Investigational Site
    • Texas
      • Houston, Texas, Соединенные Штаты, 77030
        • ImClone Investigational Site
  • Таиланд
      • Bangkok, Таиланд, 10400
        • ImClone Investigational Site
      • Chiang Mai, Таиланд, 50002
        • ImClone Investigational Site
      • Rajathevee District, Таиланд, 10400
        • ImClone Investigational Site
  • Тайвань
      • Kaohsiung, Тайвань, 807
        • ImClone Investigational Site
      • Taichung County, Тайвань, 433
        • ImClone Investigational Site
      • Taipei, Тайвань, 111
        • ImClone Investigational Site
      • Taipei, Тайвань, 116
        • ImClone Investigational Site
  • Турция
      • Adana, Турция, 01330
        • ImClone Investigational Site
      • Gaziantep, Турция, 27310
        • ImClone Investigational Site
      • Istanbul, Турция, 34718
        • ImClone Investigational Site
      • Izmir, Турция, 35100
        • ImClone Investigational Site
  • Филиппины
      • Cebu City, Филиппины, 6000
        • ImClone Investigational Site
      • Pasig City, Филиппины, 1604
        • ImClone Investigational Site
  • Хорватия
      • Osijek, Хорватия, 31 100
        • ImClone Investigational Site
      • Pula, Хорватия, 52100
        • ImClone Investigational Site
      • Slavonski Brod, Хорватия, 35 000
        • ImClone Investigational Site
      • Zagreb, Хорватия, 10 000
        • ImClone Investigational Site
  • Чехия
      • Brno, Чехия, 656 53
        • ImClone Investigational Site
      • Hradec Kralove, Чехия, 500 05
        • ImClone Investigational Site
      • Liberec, Чехия, 460 63
        • ImClone Investigational Site
      • Nova Ves pod Plesi, Чехия, 262 04
        • ImClone Investigational Site
      • Olomouc, Чехия, 775 20
        • ImClone Investigational Site
      • Pardubice, Чехия, 532 03
        • ImClone Investigational Site
      • Prague, Чехия, 180 81
        • ImClone Investigational Site
      • Praha 10, Чехия, 100 34
        • ImClone Investigational Site
      • Praha 2, Чехия, 128 08
        • ImClone Investigational Site
      • Pribram, Чехия, 261 95
        • ImClone Investigational Site
  • Чили
      • Concepcion, Чили, 407-0038
        • ImClone Investigational Site
      • La Serena, Чили
        • ImClone Investigational Site
      • Santiago, Чили, 6570917
        • ImClone Investigational Site
  • Южная Африка
      • Cape Town, Южная Африка, 7925
        • ImClone Investigational Site

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

18 лет и старше (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  • Histologically or cytologically confirmed gastric carcinoma, including gastric adenocarcinoma or GEJ adenocarcinoma
  • Metastatic disease or locally recurrent, unresectable disease with measurable lymph node metastases
  • Measurable disease and/or evaluable disease. Measurable disease is defined as at least one unidimensionally-measurable target lesion [≥ 2 centimeter (cm) with conventional techniques or ≥ 1 cm by spiral computed tomography (CT)], as defined by Response using Response Evaluation Criteria in Solid Tumors (RECIST).

Examples of evaluable, nonmeasurable disease include gastric, peritoneal, or mesenteric thickening in areas of known disease, or peritoneal nodules that are too small to be considered measurable by RECIST

  • Experienced disease progression during or within 4 months after the last dose of first-line therapy for metastatic disease, or during or within 6 months after the last dose of adjuvant therapy
  • Disease is not amenable to potentially curative resection
  • Participant is ≥ 18 years of age
  • Participant has a life expectancy of ≥ 12 weeks
  • Participant resolution to Grade ≤ 1 (or to Grade ≤ 2 in the case of neuropathy) by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 3.0, of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy (with the exception of alopecia)
  • Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score of 0-1
  • The participant has adequate hepatic function as defined by a total bilirubin ≤ 1.5 milligrams/deciliter (mg/dL) [25.65 micromole/liter (µmol/L)], and aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 x the upper limit of normal (ULN) [or 5.0 x the ULN in the setting of liver metastases]
  • The participant has adequate renal function as defined by a serum creatinine ≤ 1.5 x the ULN, or creatinine clearance (measured via 24-hour urine collection) ≥ 40 milliliters/minute (mL/min) (that is, if serum creatinine is > 1.5 x the ULN, a 24-hour urine collection to calculate creatinine clearance must be performed)
  • The participant's urinary protein is ≤ 1+ on dipstick or routine urinalysis ([UA]; if urine dipstick or routine analysis is ≥ 2+, a 24-hour urine collection for protein must demonstrate < 1000 milligrams (mg) of protein in 24 hours to allow participation in the study)
  • The participant has adequate hematologic function, as evidenced by an absolute neutrophil count (ANC) ≥ 1000 microliters (µL), hemoglobin ≥ 9 grams/deciliter (g/dL) [5.58 millimoles/liter (mmol/L)], and platelets ≥ 100,000/µL
  • The participant must have adequate coagulation function as defined by International Normalized Ratio (INR) ≤ 1.5 and a partial thromboplastin time (PTT) ≤ 5 seconds above the ULN (unless receiving anticoagulation therapy). Participant on anticoagulation therapy with unresected primary tumors or local tumor recurrence following resection are not eligible
  • If the participant has received prior anthracycline therapy as part of his or her first-line regimen, the participant is able to engage in ordinary physical activity without significant fatigue or dyspnea
  • Because the teratogenicity of IMC-1121B is not known, the participant, if sexually active, must be postmenopausal, surgically sterile, or using effective contraception (hormonal or barrier methods)
  • Female participant of childbearing potential must have a negative serum pregnancy test within 7 days prior to randomization
  • Able to provide informed written consent and is amenable to compliance with protocol schedules and testing

Exclusion Criteria:

  • Documented and/or symptomatic brain or leptomeningeal metastases
  • Experienced any Grade 3-4 gastrointestinal bleeding within 3 months prior to randomization
  • Experienced any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, within 6 months prior to randomization
  • Ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, uncontrolled thrombotic or hemorrhagic disorder, or any other serious uncontrolled medical disorders in the opinion of the investigator
  • Ongoing or active psychiatric illness or social situation that would limit compliance with study requirements
  • Uncontrolled or poorly-controlled hypertension despite standard medical management
  • Participant has a serious or nonhealing wound, ulcer, or bone fracture
  • Received chemotherapy, radiotherapy, immunotherapy, or targeted therapy for gastric cancer within 2 weeks prior to randomization
  • Received any investigational therapy within 30 days prior to randomization
  • Undergone major surgery within 28 days prior to randomization, or subcutaneous venous access device placement within 7 days prior to randomization
  • Received prior therapy with an agent that directly inhibits vascular endothelial growth factor (VEGF) or VEGF receptor 2 (R-2) activity (including bevacizumab), or any antiangiogenic agent
  • Receiving chronic antiplatelet therapy, including aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs, including ibuprofen, naproxen, and others), dipyridamole or clopidogrel, or similar agents. Once-daily aspirin use [maximum dose 325 milligram/day (mg/day)] is permitted
  • Participant has elective or planned major surgery to be performed during the course of the clinical trial
  • Participant has a known allergy to any of the treatment components
  • Pregnant or lactating
  • Known to be positive for infection with the human immunodeficiency virus
  • Known alcohol or drug dependency
  • Participant has a concurrent active malignancy other than adequately-treated nonmelanomatous skin cancer, other noninvasive carcinoma, or in situ neoplasm. A participant with previous history of malignancy is eligible, provided that he/she has been free of disease for > 3 years

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Рандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Четырехместный

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: ramucirumab
Participants receive ramucirumab, administered via intravenous infusion every 2 weeks at a dose of 8 milligrams/kilogram (mg/kg), and best supportive care (BSC) as determined appropriate by the investigator(s). Treatment will continue until there is evidence of progressive disease (PD), the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.
Биологический: ramucirumab
Administered via intravenous infusion every 2 weeks at a dose of 8 mg/kg
Другие имена:
  • LY3009806
  • ИМС-1121Б
Другой: Best Supportive Care (BSC)
BSC as determined appropriate by the investigator(s). BSC may include but are not limited to antiemetic agents, opiate and nonopiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
Плацебо Компаратор: Placebo
Participants receive injection for intravenous infusion every 2 weeks plus BSC as determined appropriate by the investigator(s). Because investigators and ancillary medical personnel will be blinded as to assignment to active therapy versus placebo, the volume of placebo to be administered will be calculated as if it were active product with a dose of 8 mg/kg. Treatment will continue until there is evidence of PD, the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.
Другой: Best Supportive Care (BSC)
BSC as determined appropriate by the investigator(s). BSC may include but are not limited to antiemetic agents, opiate and nonopiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
Лекарство: Placebo
Placebo comparator for ramucirumab 8 mg/kg as intravenous infusion every 2 weeks

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Overall Survival (OS)
Временное ограничение: Randomization up to 28 months post-randomization
Overall survival is defined as the time from the date of randomization to the date of death from any cause. Participants who were alive at the date of data cut-off or who were lost to follow-up were censored on the last date the participant was known to be alive
Randomization up to 28 months post-randomization

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Progression-Free Survival (PFS)
Временное ограничение: Randomization up to 17 months
PFS is defined as the time from date of randomization until date of objectively determined progressive disease (PD) or death due to any cause, whichever is first. Participants alive and without PD were censored at the time of last adequate objective tumor assessment (that is, response other than unevaluable).
Randomization up to 17 months
Percentage of Participants Who Are Progression-Free at Week 12 (PFS Rate)
Временное ограничение: Week 12 post-randomization
The percentage of participants alive and progression-free 12 weeks after randomization. Progression-free survival (PFS) is defined as the time from the date of randomization until the date of objectively determined progressive disease (PD) or death due to any cause whichever comes first. Participants alive and without PD were censored at the time of the last adequate objective tumor assessment.
Week 12 post-randomization
Percentage of Participants With Objective Response (Objective Response Rate [ORR])
Временное ограничение: Randomization up to 17 months post-randomization
ORR is equal to the percentage of participants achieving a best overall response of complete response (CR) or partial response (PR). CR and PR were defined using the Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR is defined as the disappearance of all target and non-target lesions, no appearance of new lesions and confirmed at the consecutive tumor assessment. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, no appearance of new lesions and confirmed at a subsequent tumor assessment.
Randomization up to 17 months post-randomization
Duration of Response (DOR)
Временное ограничение: Randomization up to 17 months post-randomization
DOR is the interval from date of initial documented response (complete response [CR] or partial response [PR]) to first documented date of disease progression (PD) or death as a result of any cause. CR and PR were defined using the Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR is defined as the disappearance of all target and non-target lesions, no appearance of new lesions and confirmed at the consecutive tumor assessment. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, no appearance of new lesions and confirmed at a subsequent tumor assessment. Participants who did not relapse or die were censored at the time of the last adequate objective tumor assessment.
Randomization up to 17 months post-randomization
Change From Baseline in Quality of Life (QoL) as Measured by the European Organisation for Research and Treatment of Cancer Questionnaire (EORTC-QLQ-C30)
Временное ограничение: Baseline up to Cycle 10 (18 weeks [1 cycle=2 weeks])
EORTC QLQ-C30 v3.0 is a self-administered questionnaire with multidimensional scales that measures 5 functional domains (physical, role, cognitive, emotional, and social), global health status, and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation and diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, higher scores represent a better level of functioning. For symptoms scales, higher scores represented a greater degree of symptoms. Best change from baseline results determined by Least Square (LS) mean estimated with randomization stratification factors and baseline value as continuous covariate.
Baseline up to Cycle 10 (18 weeks [1 cycle=2 weeks])
Number of Participants With Adverse Events
Временное ограничение: Randomization up to 18 months
Clinically significant events were defined as serious adverse events (SAE) and other treatment-emergent non-serious adverse events (NSAE). A summary of SAEs and all other NSAEs is located in the Reported Adverse Event module.
Randomization up to 18 months
Maximum Concentration (Cmax) of IMC-1121B
Временное ограничение: 6 weeks post-randomization
Cmax was not analyzed as only pre-dose samples were collected.
6 weeks post-randomization
Number of Participants Who Developed Antibodies Against IMC-1121B
Временное ограничение: Baseline, 12 Weeks
The number of participants who developed treatment emergent antibody responses to IMC-1121B after baseline.
Baseline, 12 Weeks

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Eli Lilly and Company

Публикации и полезные ссылки

Лицо, ответственное за внесение сведений об исследовании, добровольно предоставляет эти публикации. Это может быть что угодно, связанное с исследованием.

Общие публикации

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования

1 августа 2009 г.

Первичное завершение (Действительный)

1 июля 2012 г.

Завершение исследования (Действительный)

1 декабря 2015 г.

Даты регистрации исследования

Первый отправленный

8 июня 2009 г.

Впервые представлено, что соответствует критериям контроля качества

9 июня 2009 г.

Первый опубликованный (Оценивать)

10 июня 2009 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

25 сентября 2019 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

10 сентября 2019 г.

Последняя проверка

1 сентября 2019 г.

Дополнительная информация

Термины, связанные с этим исследованием

Ключевые слова

Дополнительные соответствующие термины MeSH

Другие идентификационные номера исследования

  • 13893
  • 2008-005964-15 (Идентификатор реестра: MHRA)
  • CP12-0715 (Другой идентификатор: ImClone Systems)
  • I4T-IE-JVBD (Другой идентификатор: Eli Lilly and Company)

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

ДА

Описание плана IPD

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Сроки обмена IPD

Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Критерии совместного доступа к IPD

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Совместное использование IPD Поддерживающий тип информации

  • STUDY_PROTOCOL
  • САП
  • КСО

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться